(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Interstellar comet 3I/ATLAS will fly by Earth Friday. Here are the latest images - 210 Setting up camp Shelters That Offer Both Excellence and Isolation
- 3Make your choice for the sweet that transports you to its nation of beginning!
- 4The Best Games Crossroads in History
- 5High Court freezes government move to shutter Army Radio pending ruling
- Only 30% of young people in Israel optimistic about future, Aluma survey reveals
- Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas
- A hunger for new experiences Narratives: Motivating Travel and Experience
- IAF intercepts over 90% of drones launched by Iran, Hezbollah during Operation Roaring Lion
- Governments take targeted action as fuel prices hit retail
- Scientists train to dive beneath polar ice as climate change warms the Arctic and Antarctica
- A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
- 10 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- UN rights chief: Israel's new Gaza aid agency rules 'outrageous'
